1 Investigation of the reasons for delayed presentation in proliferative diabetic

2 retinopathy patients

- 3 Meng Zhao1¶, Aman Chandra2&, Lin Liu1&, Lin Zhang3&, Jun Xu1&, Jipeng Li
- 4 1¶*
- 5 1 Ophthalmology, Beijing Tongren Eye Center, Beijing Key Laboratory of
- 6 Ophthalmology and Visual Science, Beijing Tongren Hospiospital, Capital Medical
- 7 University. No1. Dongjiaominxiang street, Dongcheng District, Beijing, 100730,
- 8 China.
- 9 2 Mid & South Essex NHS Foundation Trust (Southend University Hospital)
- 10 Prittlewell Chase Essex SS00RY, UK; Anglia Ruskin University, Cambridge, UK.
- 11 3Endocrinology, Beijing Tongren HospiatalHospital, Capital Medical University.
- 12 No1. Dongjiaominxiang street, Dongcheng District, Beijing, 100730, China.
- ¹³ * Jipeng Li, Jun Xu and Meng Zhao are Ph.DPh.D. degree
- 14 * Correspondence:
- 15 Corresponding Author: Jipeng Li
- 16 E-mail: jipeng2004@sina.com
- 17 ¶ These authors contributed equally to this work.
- 18

19 Abstract

Aim: To investigate reasons for delayed presentation in patients with proliferative
diabetic retinopathy (PDR).

Methods: A questionnaire was designed to investigate consecutive PDR patients with delayed presentation who visited our center between January 2021 and December 2021. The questionnaire was divided into four sections: knowledge regarding diabetic retinopathy (DR), attitude toward DR treatment, difficulties adhering to follow-up plans, and medical care. The systemic disease status and severity of DR were recorded. Logistic analysis was undertaken to investigate DR treatment refusal and delay factors.

Results: A total of 157 patients were included in this study, with an average age of 29 50.0 ± 11.6 years. The overall glycemic control was poor, with a median glycated 30 hemoglobin level (HbA1c) of 7.8% (IQR 2.5%). Among the 157 eyes, most required 31 vitrectomy intervention (144, 91.7%); 17 developed neovascular glaucoma (NVG), 32 while only 13 required additional photocoagulation. Among the 36 patients with 33 undiagnosed DM, the reason for delayed DR presentation was a lack of awareness of 34 DM status among these patients (36 cases, 100.0%). Most of the patients with a known 35 history of DM exhibited inadequate DR knowledge (29, 24.0%), believed their good 36 visual acuity did not require DR screening (98, 81.0%), and had poorly controlled 37 diabetes (113, 93.3%). Factors related to refusing DR treatment were patients with an 38 inability to receive regular diabetes treatment in internal medicine clinics (OR 6.78, 39

95% CI 1.73-26.59, p=0.006), patients who could not tolerate discomfort during 40 ophthalmic examination and treatment (OR 15.15, 95% CI 2.70-83.33, p<0.001), and 41 patients who did not have any retinal abnormalities detected and were not informed 42 about the need for regular screening (OR 2.05, 95% CI 1.36-3.09, p<0.001). 43 **Conclusions:** This study investigated the factors contributing to delayed presentation 44 among patients with PDR. Many individuals in the delayed population were found to 45 have undiagnosed DM. Among patients already aware of their DM status, reasons for 46 delay included insufficient knowledge about DR, negative attitudes toward screening 47 and treatment, and difficulties seeking medical care in real-life situations. Furthermore, 48 there needed to be more improvements in the detection, treatment, and follow-up of 49 DR by internal medicine practitioners and ophthalmologists. 50

52 Introduction :

Diabetic retinopathy (DR), one of the complications of diabetes, is also the leading
cause of blindness in the working-age population ^[1]. Early detection and prompt
treatment of PDR play a crucial role in reducing the risk of diabetes-related blindness
^[2, 3]. In countries implementing comprehensive screening programs for diabetic
retinopathy, the annual incidence of blindness resulting from diabetic retinopathy has
declined ^[4, 5].

However, despite the availability of national DR screening in some countries, many 59 patients still do not receive timely treatment. This issue is not exclusive to specific 60 regions, as highlighted by a national survey that revealed alarming statistics. A survey 61 found that 70.1% of DR patients identified through retinal photography were unaware 62 of their DR condition, while 23.1% of patients with known diabetes were unaware of 63 their DM status ^[6]. In China, the lack of a national DR screening program and data on 64 delayed DR presentation further exacerbates the problem. However, the increasing 65 number of cases of DR-related blindness in the country indicates a pressing need for 66 prompt action. Between 1999 and 2019, the annual incidence rate of DR-related 67 blindness in China skyrocketed from 0.06 to 0.23 cases per million population, and the 68 rate of visual impairment rose from 0.3 to 0.86 cases per million population ^[7]. 69 Examining regional data sheds further light on the extent of the issue. For instance, a 70 survey conducted among elderly residents in Beijing communities discovered that 71 87% of patients with DR were unaware of their condition. Moreover, only 28% of 72

diabetic patients had undergone DR screening within the past year [8]. Similarly, an
epidemiological survey conducted in rural northern China revealed that 12.1% of
known diabetic patients had vision-threatening DR but had not received the necessary
treatment [9]. These regional findings emphasize a significant delay in diagnosing and
treating PDR within the diabetic population in China.

Various factors contribute to the delay in the diagnosis and treatment of DR. In 78 countries where national DR screening programs have been implemented, research 79 indicates that reasons for the patient delay or nonparticipation in screening include 80 insufficient social support ^[8], poor patient compliance ^[8], inadequate awareness of 81 DR^[8], lack of DR-related visual symptoms^[9], limited opportunities for dilated fundus 82 examination^[9], restrictions on seeking medical care due to systemic diseases^[10], 83 economic factors ^[11], racial differences ^[12] pain during treatment [15], and inability to 84 achieve expected visual outcomes ^[13, 14]. 85

The prevalence of diabetes among Chinese patients has increased annually, from 10.9% in 2013 to 12.4% in 2018 [18]. Investigating the reason for the delayed presentation of PDR is crucial for preventing DR-related blindness.

Therefore, we planned to study a group of PDR patients who had not received timely treatment by using a questionnaire survey to investigate the reasons for delaying DR diagnosis and treatment and evaluate the control of diabetes, treatment of eye diseases, and severity of eye diseases. Finally, we aimed to analyze the relevant factors and reasons for delaying diagnosis and treatment in these PDR patients.

94 Material and Methods:

95 Questionnaire design (Appendix 1) :

In this study, a questionnaire survey method was used to investigate patients. The questionnaire gathered information about the patient's medical history, medication usage for systemic diseases, and ocular treatment history. The questionnaire then focused on understanding the reasons for delayed PDR presentation among the patients and was divided into four distinct sections:

a. Knowledge about DR section: This part assessed the patients' understanding of DR related knowledge before their PDR diagnosis. The assessment utilized a yes/no
 question format to evaluate the patients' knowledge.

b. Attitude toward DR treatment section: This section aimed to gain insights into the
patients' attitudes toward the diagnosis and treatment of DR. It also aimed to identify
subjective reasons for treatment delay by providing a list of various reasons for patients
to choose from. Additionally, patients were asked whether they had ever refused DR
treatment.

c. Difficulties in real-life section: This section investigated the social, economic, and
systemic factors that patients believed could impact their willingness to seek DR
diagnosis and treatment. It included questions related to insurance coverage, financial
income situation, level of family support, and whether the patients were influenced by
factors such as work, caregiving responsibilities, or other systemic diseases. Multiplechoice selection was utilized in this section.

d. Medical processes section: This section explored the patients' experiences with
different medical processes, explicitly focusing on interactions with internal medicine
physicians and ophthalmologists. It included inquiries about whether the internal
medicine physicians or ophthalmologists provided DR education and informed their
patients about the importance of regular fundus examinations or check-ups.

By structuring the questionnaire into these four sections, the study aimed to comprehensively investigate patients' knowledge, attitudes, obstacles, and experiences with medical processes related to DR diagnosis and treatment.

123 **Cross-sectional survey:**

The population to be surveyed in this study consisted of consecutive patients diagnosed with PDR during outpatient visits to our hospital between January 2021 and December 2021 who did not receive timely treatment. The study followed the tenets of the Declaration of Helsinki and the protocol and was approved by the Institutional Review Board of Beijing Tongren Hospital. Patients were required to sign an informed consent form and written informed consent was obtained from each participant prior to commencing the survey.

Inclusion criteria: 1) patients had to be between 18 and 70 years of age; 2) patients must have been diagnosed with PDR requiring photocoagulation or vitrectomy in at least one eye; 3) patients had to show a delayed PDR presentation, defined as those who were diagnosed with PDR but did not receive treatment during their initial outpatient visit or those who received treatment but did not undergo timely follow-up, failing to

detect disease progression; 4) patients must have completed all laboratory tests
(including routine blood, urine, and renal function tests) or have had a precise diagnosis
of systemic complications; 5) patients must have completed the questionnaire survey;
6) patients must have agreed to participate in the study.

Exclusion criteria: 1) patients with severe vitreous hemorrhage (VH) for which it 140 could not be determined if PDR was the cause; 2) patients in whom both eyes had 141 undergone vitrectomy due to PDR, making it impossible to determine if PDR was 142 delayed before the surgery; 3) patients who currently did not require laser or PPV 143 surgery but only needed close follow-up observation; 4) patients who were unable to 144 complete the survey questionnaire; 5) patients with comorbidities such as glaucoma, 145 optic nerve disease, or macular detachment, as these conditions may cause irreversible 146 vision loss; 6) patients who were in lockdown during the COVID-19 pandemic in 147 Beijing and were excluded from the study due to the limited availability of appointments 148 for DR patients, which could have resulted in delays in their treatment. 149

The selected patients underwent a comprehensive ophthalmic examination, including a corrected visual acuity test, intraocular pressure test, and slit-lamp assessment to evaluate the presence of neovascularization of the iris (NVI) and indirect ophthalmoscopy and vitrectomy if needed to determine the severity of PDR. PDR patients were diagnosed as those who required only photocoagulation or required vitrectomy. In addition, the presence of combined NVI or NVG was recorded.

The patients then completed the questionnaire survey. The general condition, overall health status, and history of ocular treatment details were recorded as follows: the

diagnosis of combined hypertension; combined diabetic complications; history of 158 participating in a DR screening program; the time between the last screening and 159 diagnosis if they participated; the refusal of DR screening or PDR treatment 160 recommendations; history of phacoemulsification cataract extraction, intravitreal 161 injection (IV) of anti-vascular endothelial growth factor (VEGF) agents, or pan-retinal 162 photocoagulation (PRP) treatment; and whether the patients were followed up on time 163 after examinations or treatments. The results of the four-section questionnaire on 164 reasons for delayed presentation of PDR were recorded. 165

The laboratory examination on HbA1C and questionnaire items on controlling blood glucose were recorded for further analysis of glucose control status. The renal function test result was recorded to determine the presence of chronic kidney disease (CKD) with impaired renal function.

Incomplete laser treatment was defined as adding 500 or more laser spots duringoutpatient photocoagulation or surgical procedures.

PDR patients with neovascularization elsewhere (NVE) but without high-risk PDRwere only treated with PRP.

PDR that required vitrectomy was defined by the presence of any of the following conditions: 1) VH that hinders further examination of the fundus, confirmed as PDR during surgery, 2) fibrovascular membranes involving or threatening the macula or associated with recurrent vitreous hemorrhage, and 3) VH due to PDR combined with NVI or NVG.

In cases where treatment was required for both eyes, the eye with better visual acuity
 9

and a milder disease condition was selected as the study eye.

181 Grouping:

The patient's acceptance of their DR diagnosis and treatment is directly related to 182 their awareness of having DM. Therefore, there are inevitably differences in the reasons 183 for delayed presentation, DR-related knowledge, and DM control between PDR patients 184 with undiagnosed DM and those with a clear history of DM who did not receive timely 185 PDR diagnosis and treatment. The former group has never received diabetes treatment 186 before being diagnosed with PDR, while the latter often faces issues causing delays in 187 PDR diagnosis and treatment during the DM treatment process, despite being diagnosed 188 with diabetes early on. In the subsequent investigation of the population known to have 189 DM, we further classified them based on the following question in the survey 190 questionnaire: "Have you ever refused the doctor's recommendation for DR diagnosis 191 and treatment?" This latter group was divided into a non-compliant group (refusing DR 192 diagnosis and treatment) and a compliant group (accepting DR screening or therapy). 193 The compliant group included patients who underwent screening but were 194 misdiagnosed as not having PDR and patients who received photocoagulation treatment 195 but still had worsening conditions. 196

PDR patients with undiagnosed DM: Defined as patients who sought ophthalmic
 care due to ocular symptoms, where retinal abnormalities were discovered, leading
 to a diagnosis of DR, but who had not previously undergone DM screening or
 treatment were unaware of having DM during initial ophthalmic consultation.

201 2. PDR patients with a clear history of DM at the time of PDR diagnosis: This group
202 of patients was further divided into two subgroups:

- 203 2.1. Patients who were able to complete DR screening and treatment as required:
 204 Defined as patients who have previously undergone DR screening and treatment
 205 as instructed by their doctor before the current visit, including one of the three
 206 following conditions:
- 207 2.1.1. Patients with underdiagnosed PDR: Defined as patients with a confirmed history
 208 of DM who underwent eye DR screening within the last six months as required
 209 but had negative findings and were diagnosed with PDR during the current visit.
- 2.1.2. Patients with PDR progression despite previous PRP treatment: Defined as
 patients with a confirmed history of DM and DR who had previously undergone
 PRP treatment as required but whose condition progressed to the extent that extra
 photocoagulation or surgical treatment was needed.

2.2 Patients who refused to participate in DR screening and treatment: Defined aspatients previously advised to undergo DR screening or treatment but refused.

216 Statistical analysis:

Statistical analysis was performed using R version 3.20 (http://www. R-project.org). Patient characteristics were retrieved from their medical charts and recorded in Epidata Entry Clientversion2.0.3.15 (http://epidata.dk). The mean and standard deviation (SD) were calculated for continuous variables with a normal distribution. The median with quartiles was calculated for continuous variables with nonnormal distribution. The t-test

or Mann–Whitney U test was carried out for continuous variables. The chi-square or
Fisher's exact test was carried out for discrete data.

To investigate the factors related to patients refusing to undergo DR screening or 224 treatment, two independent-sample comparisons were carried out on characteristics 225 between patients who could complete DR screening and treatment as required and 226 patients who refused to participate in DR screening and treatment. Variables with a p-227 value less than 0.3 were further enrolled in a binary backward stepwise logistic 228 regression model. Each time, one variable was included or excluded from the model by 229 comparing the Akaike information criterion (AIC) value; the model with the lowest AIC 230 was chosen. 231

232 **Results:**

233 General Characteristics :

A total of 157 patients, with a mean age of 50.0 ± 11.6 years and including 84 male patients (53.5%), were included in this study. The overall glycemic control was poor, with a median HbA1c of 7.8% (IQR 2.5%).

Most 157 eyes (144, 91.7%) required vitrectomy intervention; 17 developed NVG,
while only 13 required additional PRP.

PDR was confirmed in most contralateral eyes (154, 98.1%), with 3 cases of blindness
due to trauma. Most of these eyes did not receive timely and effective treatment,
resulting in 18 cases of blindness due to PDR, five patients treated with vitrectomy, 42

242 cases treated with PRP, and 10 cases treated with intravitreal injection (IV) of anti-

vascular endothelial growth factor (VEGF) agents (details in Table 1).

Table 1 Characteristics of Diabetic patients in different groups

	Patients	Patients with a history of DM (121)		
	with	Patients who	Patients who w	vere able to
	undiagno	refused to	complete DR s	creening and
	sed DM	participate in DR	treatment as re	quired
	(36)	screening and	underdiagnos	Progressed after
		treatment (75)	ed PDR (30)	PRP (16)
age (y,	46.3±11.	51.6±11.0	47.5±11.8	54.9±13.3
mean±S	0			
D)				
DM	0.6, 1.1	13.0, 6.5	15,7.8	20, 4.5
duration				
(y,				
median,				
IQR)				
HbA1c	7.2, 2.5	7.6, 2.6	8.6,2.7	7.5, 2.1
(%, IQR)				
herb	2	2	1	1

without				
other				
medicati				
on (n)				
HTN (n)	25	35	18	9
CKD (n)	11	17	20	5
coronary	9	10	9	4
heart				
disease				
(n)				
stroke (n)	3	6	5	3
Ocular	3.5, 9.3	3.0, 7.0	4.0, 4.0	4.5, 10
symptom				
(m,				
median,				
IQR)				
Cataract	6	1	1	0
extractio				
n without				

DR				
screening				
(n)				
IV-anti	3	4	3	2
VEGF				
(n)				
incomple	6	7	5	7
te PRP				
(n)				
complete	2	4	2	3
PRP (n)				
Further tre	eatment			
required	3	6	1	3
PRP (n)				
required	30	42	27	12
vitrectom				
y without				
NVG (n)				
required	3	7	2	1
vitrectom				

245	SD:	y with	
246	standard	NVG (n)	
247	deviation,	IQR: interquartile range, HbA1c: glycated form of hemoglobin, HTN:	
248	hypertension, CKD: chronic kidney disease, IV: intravitreal injection, VEGF: vascular		
249	endothelial growth factor, PRP: pan retinal photocoagulation, NVG: neovascular		
250	gluacoma		

251

252 Patient-related reasons for delayed presentation :

253 Patients with undiagnosed DM at the diagnosis of PDR:

We identified 36 patients who were unaware of their DM diagnosis at the time of 254 PDR diagnosis. The primary reason for delayed DR presentation was that these patients 255 were unaware they had DM (36 cases, 100.0%). Additionally, some patients believed 256 that ophthalmic examination was only necessary when visual acuity significantly 257 declined or had a noticeable impact on their daily lives (14 cases, 38.9%). Furthermore, 258 a few patients believed traditional Chinese herbal therapy could cure DM and did not 259 undergo systematic evaluation even after receiving suggestions to rule out DM (4 cases, 260 11.2%). Notably, 14 (38.9%) did not have medical insurance, seven (19.4%) had 261 economic difficulties, six (16.7%) had caregiving responsibilities, five (13.9%) had 262 trouble taking time off from work, and 5 (13.9%) had concurrent management of other 263 systemic diseases. These factors were identified as contributing to delayed medical 264

attention. None of the patients had undergone a physical examination in the past year.
Due to patients' lack of awareness of their DM diagnosis, we did not investigate their
compliance with blood glucose control and knowledge of DR.

268 Patients with a clear history of DM at the diagnosis of PDR:

We surveyed 121 PDR patients with a known history of diabetes to explore the reasons and personal factors contributing to their delay in DR treatment. The survey included patients' acknowledgment of DR, compliance with DM management, and attitudes toward DR diagnosis and treatment. Some patients were not opposed to DR treatment but had other issues, while others directly resisted DR treatment. We conducted separate investigations for these two groups.

First, we identified common issues among patients with a known history of DM who experienced delays in PDR diagnosis and treatment:

In terms of DR awareness, the patients generally exhibited inadequate knowledge. Only 29 (24.0%) individuals knew that diabetic patients require regular DR screening, and only 33 (27.3%) knew that untreated DR could lead to blindness.

In terms of behavior, patients attributed the primary reason for the delay to their excellent visual acuity, leading them to believe that DR screening was unnecessary. Ninety-eight (81.0%) patients thought their good visual acuity was the main reason for delaying DR diagnosis and treatment.

Regarding compliance with DM management, most patients (113/121, 93.3%) reported regular use of diabetic medication, but their glycemic control was poor. Among

them, 22 patients (18.2%) had an HbA1c level above 6.5% at their visit.

Furthermore, we revealed the characteristics of patients who refused DR screening or treatment and the reasons for the refusal.

The two groups of patients showed similar levels of DR awareness in the survey regarding reasons for delay (p=0.41, p=0.83), and there were no significant differences in social support (p=0.98) or insurance coverage (p=0.99).

Compared to diabetic patients who did not refuse the recommended DR screening 292 and treatment, those who refused exhibited the following characteristics: a lower 293 proportion of regular visits to internal medicine clinics (43/75, 42/46, p<0.001), a 294 shorter duration of diabetes (13, 16, p=0.005), a higher proportion of patients with no 295 abnormalities detected during screening but no regular follow-up recommended (49/75, 296 14/46, p<0.001), and a lower proportion of patients able to tolerate discomfort during 297 DR examination or treatment (17/75, 3/46, p=0.02). Furthermore, logistic regression 298 analysis revealed three factors associated with the refusal of DR diagnosis and treatment: 299 A. Inability to receive regular diabetes treatment in internal medicine clinics (OR 6.78, 300 95% CI 1.73-26.59, p=0.006), 301

- B. Inability to tolerate the discomfort during ophthalmic examination and treatment
 (OR 15.15, 95% CI 2.70-83.33, p<0.001),
- C. Patients who did not detect any retinal abnormalities and were not informed about
 the need for regular screening (OR 2.05, 95% CI 1.36-3.09, p<0.001) (AIC=118.88,
 AUC=0.861).

Patient-perceived reasons for delayed presentation related to medical, family, and social aspects:

After investigating the reasons for the delay as perceived by themselves, we further examined the difficulties that could lead to delays, including financial problems, work distractions, family caregiving responsibilities, inability to seek medical attention independently, and the need to treat other systemic diseases. The ranking of these reasons varied among different patient groups (Figure 1).

For individuals who were unaware of their DM diagnosis at the time of PDR diagnosis, the factors influencing their DR treatment were as follows: financial difficulties (16.7%), being occupied by work (16.7%), family caregiving responsibilities (14.9%), and the need for treatment of other systemic diseases (11.9%).

For the PDR patients who refused DR treatment suggestion, the factors influencing
 their participation in DR screening were as follows: the need for treatment of other
 systemic diseases (16.0%), being occupied by work (12.0%), lack of accompanying
 during medical visits (8.0%), and financial difficulties (5.3%).

323 3. For the PDR patients with underdiagnosed DR, the factors influencing their situation
were as follows: the need for treatment of other systemic diseases (26.7%), being
occupied by work (13.3%), financial difficulties (10.0%), and lack of accompanying
during medical visits (2.9%).

4. For the PDR patient experiencing disease progression after PRP treatment, the

328	factors influencing their situation were as follows: the need for treatment of other
329	systemic diseases (31.3%), lack of accompanying during medical visits (25%),
330	financial difficulties (25%) and being occupied by work (30%).
331	
332	Figure 1 The radar chat for the patient-perceived reasons for delayed
333	presentation among different groups.
334	
335	Deficiencies in the healthcare services in response to the delayed presentation:
336	In addition to the patients and their support system, we identified deficiencies in
337	DM screening, the management of diabetic patients by internal medicine physicians,
338	and the treatment for DR provided by ophthalmologists, all contributing to delays in
339	DR management.
340	Inadequate DM screening among the general population:
341	Our study identified 36 patients diagnosed with DM only when PDR was detected
342	in the ophthalmology clinic. These patients had not undergone DM screening
343	previously. For them, the main issue contributing to treatment delay is why DM was
344	not detected promptly.
345	Issues with internal medicine physicians in DR management:

346 After being diagnosed with DM, patients most frequently interact with internal

medicine physicians. Among patients with a known history of DM but who
experienced treatment delays, we identified problems related to guidance on regular
visit, education on DR, and the sensitivity of DR screening by internal medicine
physicians.

Internal medicine physicians did not emphasize the importance of regular follow-up 351 visits for DM patients. Our study found that among individuals with known history of 352 DM, 36 patients (29.75%) did not have regular visits to internal medicine physicians. 353 Furthermore, the proportion of patients who did not have regular visits and underwent 354 DR screening was lower. This was evident in the following aspects: 1) a lower 355 proportion of patients who received information from internal medicine physicians 356 about the potential blindness caused by DR, compared to those with regular visits 357 (4/36, 29/85, p=0.01); 2) a lower proportion of patients with irregular visits who 358 underwent DR screening, compared to those with regular visits (11/36, 67/85, p=0.01). 359 We found a lack of DR education among internal medicine physicians. Among the 360 121 patients known to have DM, only 18 individuals (14.9%) received DR education 361 from internal medicine physicians, which was significantly lower than the proportion 362 of patients receiving DR education from ophthalmologists (18/121 vs 62/121, 363 p<0.001). Even among the 85 patients with regular visits, only 25 individuals were 364 aware of the importance of regular fundus examinations. The majority of patients 365 obtained knowledge about DR through ophthalmic DR screening, and those who 366 underwent DR screening had better awareness of DR compared to those who did not 367 undergo screening (DR screening necessary: 40/66 vs 81/91, p<0.001; DR can cause 368

369 blindness: 46/66 vs 80/91, p=0.008).

During the initial visit for DM, internal medicine physicians did not sufficiently emphasize the potential for blindness due to DR and the importance of regular asymptomatic DR examinations. Among the 55 patients who refused retinal screening, 87.3% believed that good vision meant they did not need screening, which was the primary reason for their refusal. Additionally, we found that 14.5% of patients delayed DR screening out of fear of detecting retinal abnormalities.

We observed a low sensitivity of DR screening initiated by internal medicine 376 physicians. This could lead patients to mistakenly believe that their fundus are normal 377 and overlook the importance of regular follow-up examinations. Our study identified 378 30 patients who underwent DR screening within the past six months without detecting 379 380 any retinal abnormalities. However, within the subsequent six months, 29 patients developed PDR retinal lesions requiring surgical intervention, including two 381 individuals who developed NVG. Among them, 20 patients had undergone DR 382 screening initiated by internal medicine physicians, while ten had undergone screening 383 initiated by ophthalmologists. The rate of missed diagnosis in DR screening initiated 384 by internal medicine physicians was 20/21, significantly higher than that of 385 ophthalmologists, which was 10/45 (p<0.001). 386

Internal medicine physicians did not adequately emphasize the need for regular DR screening when DR was not detected. Our findings demonstrated that among patients who underwent initial screening without detecting DR, those who were not informed about the importance of regular follow-up had fewer opportunities for PDR treatment

compared to those who were notified. Among the 30 patients with negative retinal 391 findings during the initial screening, 14 individuals were not informed about the need 392 for follow-up, and 12 were not informed by internal medicine physicians. These patients 393 did not receive PDR treatment during the subsequent six months. On the other hand, 16 394 patients were informed about the need for regular follow-up. During the subsequent 395 examinations, they were diagnosed, with two individuals receiving the opportunity for 396 complete PRP treatment and five individuals completing partial PRP treatment before 397 the onset of vitreous hemorrhage (0/14, 7/16, p=0.007). 398

Our investigation revealed that 28 patients experienced delays in DR treatment due to hospitalization for systemic diseases. These patients did not receive ophthalmic consultations or treatment during their hospital stay, nor did they receive any educational information about DR from internal medicine physicians.

We identified 8 PDR patients who regularly sought treatment from traditional 403 Chinese medicine (TCM) practitioners. These patients were of working age, ranging 404 from 33 to 62 years old, with a median age of 59 (standard deviation 7.75 years). 405 However, these patients relied solely on TCM instead of receiving systematic glucose-406 controlling medicine (6/8), resulting in poor blood glucose control (elevated glycated 407 hemoglobin levels, with an average of 7.1 ± 1.1) and severe systemic complications 408 (8/8). Prior to their diagnosis of PDR, these patients lacked awareness of DR, unaware 409 of its potential to cause blindness and the need for regular examinations (8/8). 410 Furthermore, none underwent ophthalmic DR screening (8/8), leading to the 411

412 development of PDR complications requiring surgical intervention.

413 Insufficiencies in the Diagnosis, Treatment of DR by Ophthalmologists:

414	Ophthalmologists are responsible for treating DR, particularly in emphasizing the
415	importance of regular follow-up for early-stage DR that does not affect vision.
416	However, we found that DR patient education inadequately emphasizes this
417	importance. Only 62 out of 121 patients received DR education from
418	ophthalmologists. Additionally, a considerable proportion of patients who received
419	DR treatment falsely believed that having good VA meant they did not require
420	ophthalmic care and postponed seeking medical attention. This behavior was similar
421	to that of patients who did not comply with the recommended DR treatment (39/46,
422	59/75, p=0.55).

Ophthalmologists have shown insufficient efforts in educating and encouraging 423 patients who exhibit resistance and pain-related concerns during DR treatment. 424 Alternatively, the understanding of patients may have needed to be improved despite 425 information from ophthalmologists. We discovered that discomfort experienced during 426 fundus examinations and PRP therapy became the primary reasons for delayed 427 presentation of DR. When investigating the reasons behind delayed medical 428 intervention among different patient groups, we found that 65% of patients who refused 429 PDR treatment did so out of fear of pain associated with PRP therapy. Similarly, among 430 patients who experienced disease progression after PRP treatment declined and refused 431 432 to complete the treatment due to pain related to PRP therapy. Furthermore, four individuals who refused fundus examination within the group declined PRP treatment 433

due to discomfort. In the group where improper PRP treatment resulted in DR 434 progression, three patients declined subsequent follow-ups due to discomfort during eye 435 examinations post-PRP treatment. These patients exhibited insufficient awareness 436 regarding the risk of blindness associated with DR and the necessity of regular follow-437 up examinations (10 patients, 50%, among those who refused treatment, and four 438 patients, 66.7%, among those who completed treatment but did not undergo follow-up 439 examinations). As a result, they lacked the necessary determination to overcome 440 discomfort and complete the required examinations and treatment. 441

We found that ophthalmologists needed to adequately emphasize the possibility of 442 disease progression and the importance of regular follow-up examinations after PRP 443 treatment, as demonstrated by the patient's lack of knowledge. Among the 16 patients 444 who completed PRP therapy, 11 were unaware of the need for regular follow-up 445 examinations after treatment. Despite relatively stable vision in these patients (11/16), 446 factors such as being occupied by work, systemic illnesses, family responsibilities, 447 financial difficulties, and discomfort with examinations and PRP treatment contributed 448 to their failure to attend follow-up appointments. As a result, ten patients experienced 449 disease progression to a stage requiring vitrectomy. 450

Furthermore, we found that some ophthalmologists performed PRP treatment with inadequate coverage, leading to delays in disease management. Six patients were informed of completing PRP treatment, and their condition progressed to PDR requiring vitrectomy. However, during the surgery, it was discovered that the PRP coverage was insufficient. These patients did not attend follow-up examinations promptly after

456 completing PRP treatment.

Some ophthalmologists overlooked DR screening when performing cataract extraction surgery on diabetic patients. Among the ten patients who underwent cataract extraction surgery before receiving DR treatment, seven individuals with improved vision underwent no retinal screening. In comparison, only one out of the three patients whose vision did not improve underwent DR screening, leading to a missed diagnosis. The improvement in visual acuity following cataract extraction surgery may have contributed to the delay in the diagnosis and treatment of DR.

464 **Discussion:**

Early detection and intervention can prevent blindness caused by DR^[4, 5], so delayed 465 treatment may result in severe and regrettable consequences. In China, the incidence 466 of blindness caused by DR is rapidly increasing, becoming an essential factor in the 467 rise of the blindness rate ^[7]. The factors leading to the delayed presentation of DR in 468 Chinese diabetic patients are complex and diverse; however, there are currently no 469 reports on the reasons for it. Investigating the reasons for the delayed presentation of 470 DR in diabetic patients is significant for preventing and treating blindness caused by 471 DR. 472

473 The specific DM population that the ophthalmologist should pay more attention
474 to:

1. Patients with poor diabetes control:

Our investigation revealed that this group of diabetic patients commonly exhibited 476 poor blood glucose control, which may lead to rapid DR progression. Specifically, we 477 observed that patients had elevated HbA1c (with a median of 7.8%), and only 18.2% 478 had their HbA1c controlled below 6.5% at their visit. It is established that poor blood 479 glucose control is associated with microvascular complications in diabetic patients ^[15]. 480 Studies have shown that individuals with HbA1c between 6.5 and 6.9 have a 2.35 times 481 higher risk of developing DR within three years than those with HbA1c between 5 and 482 5.4^[16]. Therefore, based on our inference, poor blood glucose control is an essential 483 factor contributing to the rapid progression of DR in the population with the delayed 484 presentation in our study. Ophthalmologists should pay special attention to and provide 485 education specifically for this population. 486

487 2. Patients with a high possibility of refusing DR treatment:

We compared patients who refused DR treatment suggestions with those who accepted them to investigate the factors associated with refusal. Ophthalmologists should be attentive to patients with the following characteristics, as they are more likely to be less engaged in DR treatment. Targeted education and follow-up should be provided to these patients to slow the progression of DR. Patient information leaflets, or website education may also allow patients to review and revise the issues.

A. Patients who do not visit internal medicine regularly are more prone to refuse DR
 treatment. Compared to patients who do not visit internal medicine regularly, those
 who have regular visits have a 6.78 times higher chance of receiving timely DR
 treatment. This could be attributed to regular patients receiving more DR education

498 (29/85, 4/36) and more DR screening opportunities (67/85, 11/36).

B. Patients who exhibit intolerance to pain and discomfort during examinations and 499 treatment are more likely to refuse DR treatment. The likelihood of refusing DR 500 treatment increased by 15.15 times for patients who strongly resisted pain and 501 discomfort compared to those who were less resistant. This resistance is particularly 502 evident among patients who refuse DR treatment (13/20), whereas factors related to 503 delays in PRP treatment due to hospitalization for systemic diseases accounted for 504 only 5/20 cases. Furthermore, previous studies have shown that fear of discomfort 505 during ophthalmic examinations is a primary reason patients refuse DR screening 506 [10,24]. Surveys regarding satisfaction with PRP treatment indicate that insufficient 507 knowledge about laser treatment^[17], discomfort caused by pupillary dilation^[17], pain 508 during laser treatment ^{[17] [18]}, and failure to achieve expected visual acuity ^[13, 14] may 509 lead to patient reluctance towards PRP treatment, thereby affecting compliance with 510 laser treatment and subsequent follow-up examinations. The results of our study 511 align with previous research. 512

C. Patients unaware of the need for regular follow-up after DR screening and with no
positive DR finding were more likely to refuse visits for DR screening. Compared to
patients advised of timely treatment and had DR detected during screening, those
who did not receive regular follow-up advice and had no evidence of DR during
screening were 2.05 times more likely to refuse DR screening or treatment.
Guidelines recommend annual retinal examinations for diabetic patients without DR
In our study, a group of patients (30/121) had no DR detected during their initial

screening but progressed to PDR within the following six months. Most of these 520 patients' DR screenings were conducted by internal medicine doctors (20/30), 521 indicating the possibility of missed diagnoses. However, these patients shared the 522 common characteristics of f long time of poor blood glucose control, with a median 523 HbA1c of 8.6 and a median duration of DM of 15 years. It was suggested that 524 individuals with a long duration of DM and poor blood glucose control might 525 experience rapid progression of DR, even if abnormalities are not initially detected. 526 Annual follow-up examinations may delay the diagnosis, indicating the need to 527 shorten the interval for DR screenings. 528

529 Reducing delays requires joint efforts from society and healthcare professionals:

530 **Practical difficulties:**

After investigating the self-perceived factors contributing to delays in our study, we referred to common reasons reported in previous studies, such as economic difficulties [11], lack of nearby medical facilities, other commitments, and hospitalization ^[8, 10], to examine the barriers identified by patients that hindered their adherence to regular DR treatment.

We identified several social factors that can influence the timely receipt of DR treatment among diabetic patients. These factors should receive greater attention and improvement in receiving similar diabetic patients in the future to provide timely DR treatment for diabetic patients.

540 Some low-income or uninsured patients did not have the opportunity to undergo 29

diabetes screening. Among patients unaware of their diabetes diagnosis when diagnosed 541 with PDR, a considerable portion consisted of low-income individuals without health 542 insurance. These patients are typically younger, with 14 (38.9%) lacking health 543 insurance and 7 (19.4%) stating they could not seek medical care due to economic 544 difficulties. Many patients missed medical visits due to obligations such as caring for 545 family members or work, and these patients had not undergone regular health check-546 ups in the past year. Therefore, efforts should be made to enhance diabetes screening 547 for individuals without health insurance or facing economic difficulties to identify 548 individuals with diabetes at an early stage and facilitate subsequent DR screenings for 549 these patients. 550

The absence of a companion may pose a barrier for diabetic patients to attend DR 551 552 treatment. Patients consider the lack of a companion during medical visits a primary challenge in receiving DR treatment. This situation is particularly prominent among 553 patients who refuse DR treatment (6/20) and those who have completed PRP treatment 554 but have no regular follow-up examinations (4/16). PDR can impact patients' 555 independent living abilities ^[19], causing inconvenience in their daily lives. Therefore, 556 for diabetic patients with visual impairments, family members are encouraged to 557 accompany them during medical visits to help provide them with more opportunities to 558 receive DR treatment. 559

The inability to take time off from work may hinder diabetic patients from attending
DR treatment. According to our research, 10.9% of patients who refuse DR screening
stated that the inability to take time off work was the reason for not being able to undergo

timely screening. Similarly, 13% of patients with missed DR diagnoses and 18.7% of 563 patients who completed PRP treatment believed that the inability to take time off work 564 was the reason for not being able to attend scheduled DR follow-ups. It is crucial to 565 identify their concerns about needing help to take leave during the initial consultation 566 and provide individualized guidance and support. It is essential to be cognizant that 567 patients with end-stage DM disease, such as PDR, are likely to have numerous medical 568 appointments, and the impact on their work can be extensive. Physicians or 569 ophthalmologists should provide adequate patient education to enhance treatment 570 compliance. 571

572 Medical care:

Our investigation found that the reasons for treatment delay among patients are 573 attributed to the patients and the factors related to the treating physicians. The 574 treatment process for DM involves a complete chain of care, starting from the initial 575 diagnosis of DM to DM follow-ups, to DR screening, and finally, the diagnosis and 576 treatment of DR. However, if any link in this chain encounters issues, it can delay 577 patient treatment. Therefore, physicians and ophthalmologists need to strengthen their 578 attention and management at each stage of the treatment chain to ensure that patients 579 receive timely care. 580

a. There are deficiencies in the DM patient education provided by physicians and
 ophthalmologists, primarily regarding dispelling the misconception that regular DR
 screening is unnecessary as long as their vision is not deteriorating. Our research

revealed that 81.0% of delayed patients believed that good vision meant they did 584 not need medical attention. This misconception was prevalent among patients 585 receiving regular internal medicine care (60/85) and those undergoing ophthalmic 586 DR treatment (59/75). It reflects a need for more emphasis on the importance of 587 early DR screening by the physicians and ophthalmologists attending to these 588 patients. Studies have shown that patients' understanding of the potential blindness 589 caused by the delayed detection of DR directly influences their adherence to DR 590 treatment ^[9]. Insufficient awareness of the need for DR screening and the 591 misconception that good vision eliminates the need for ocular examinations are 592 associated with the severity of proliferative diabetic retinopathy (PDR) when 593 diabetic patients seek ophthalmic care ^[20]. Therefore, patient education for diabetic 594 patients should focus on the importance of regular follow-ups for early DR 595 detection, irrespective of visual symptoms. During consultations with diabetic 596 patients, every opportunity should be seized to emphasize that early-stage DR may 597 not affect vision, the need for regular DR screening, and the significance of early 598 detection and treatment. 599

600 b. Some errors made by the physicians:

When diagnosing and treating systemic diseases, internal medicine physicians should also pay attention to diagnosing and treating DR. We found that 28 patients had delayed DR presentation due to treating their systemic conditions. Previous studies have indicated that hospitalization in internal medicine is a major factor contributing to delays in PRP treatment ^[10], which aligns with our research findings.

Therefore, while treating systemic diseases, internal medicine physicians should promptly seek ophthalmic consultations when feasible to ensure timely diagnosis and treatment of DR.

During internal medicine follow-ups for DM, attention should be given to patients 609 with psychological issues. In this study, 14.5% of patients refused DR screening due 610 to concerns about discovering retinal abnormalities. This reason was not mentioned 611 in previous research. The majority of these patients do not actively seek ophthalmic 612 screenings, even though they have some understanding of DR and its screening. They 613 experience excessive anxiety about potential positive test results. The prevalence of 614 depression (25%) and anxiety (13.5%) is relatively high among DR patients in our 615 country, and social support can alleviate anxiety and depression in these patients ^[21]. 616 Internal medicine physicians should promptly identify patients with abnormal 617 psychological emotions and provide positive guidance, such as informing them that 618 having DR does not inevitably lead to blindness and that timely treatment can slow 619 down disease progression and stabilize vision. It is also essential to seek the 620 cooperation and support of family members and encourage patients to undergo DR 621 diagnosis and treatment. 622

The sensitivity of DR screenings initiated by physicians needs to be improved. In this study, physicians' missed DR diagnosis rate was 20/21, which is relatively high. Previous research has shown that the sensitivity of non-mydriatic single-field fundus photography and DR interpretation initiated by internal medicine physicians is 86.6% with a specificity of 78.6% ^[22], indicating their potential role in DR screenings.

However, our study's sensitivity of DR screenings was much lower than the above 628 data, meaning there is still room for improvement among our physicians. Recent 629 studies have demonstrated that fundus photography initiated by physicians and 630 remote image reading can enhance the accuracy of DR screening ^[23]. Therefore, 631 improving the sensitivity of DR screening by physicians or implementing reliable 632 remote network image reading guidance may play a crucial role in the timely 633 detection of DR in DM patients who do not seek ophthalmic care. Alternatively, 634 trained nonphysician graders have been demonstrated to be highly successful. In the 635 UK, this has reduced the impact of diabetic eye disease-related blindness ^[24]. 636

Additionally, we found that among the 20 PDR patients with missed diagnoses in DR screenings initiated by physicians, 14 needed to be made aware of the need for regular follow-up visits. These patients did not pursue further ophthalmic care due to their excellent vision. It suggests that physicians and other health care professionals involved in their care needs must further strengthen patient education and urge patients to undergo ophthalmic follow-up visits.

There are also issues with TCM regarding DR screenings and patient education. We identified eight patients receiving treatment in TCM internal medicine who opted for traditional Chinese medicine instead of glycose-controlled medicine. This resulted in poor blood sugar control (HbA1c 7.1 [1.1]), no DR screenings, and delayed treatment until severe PDR developed. Additionally, they had uncontrolled systemic complications (high rates of HTN (6/8), CKD (4/8), and a high proportion of CAD (3/8) that were not addressed by internal medicine treatment. These patients,

aged between 32 and 62, belong to the working-age population. Once life-650 threatening and vision-threatening complications occur, they will burden society 651 significantly. Previous studies have shown that traditional Chinese medicine (TCM), 652 as a benefit as an adjunct to conventional treatment for DM, including medication, 653 exercise, and dietary control, may affect controlling HbA1c levels and improving 654 vision ^[25, 26]. Therefore, it is essential to enhance the understanding of TCM 655 physicians regarding DR screenings. When diagnosing DM, patients should be 656 informed about the importance of medication, diet, exercise, blood sugar control, 657 and glycose-control medicine treatments. Simultaneously, patients should be 658 encouraged to undergo DR screenings to minimize treatment delays caused by solely 659 focusing on vision changes. 660

661 c. The ophthalmologists should make some improvements:

Ophthalmologists' failure to remind patients who have undergone cataract 662 extraction about the importance of DR-related fundus examination can delay 663 treatment for diabetic patients who experience improved vision post-surgery. Ten 664 patients with a history of cataract extraction were included in this study, of which 665 eight did not undergo DR screening. Among these eight patients, seven reported 666 improved vision after the surgery, and five of them did not receive a fundus 667 examination because they believed their vision was already good. Previous research 668 has indicated that vision improvement following cataract surgery in diabetic patients 669 can potentially mask vision symptoms caused by DR. Additionally, cataract surgery 670 in diabetic patients can contribute to the progression of PDR, necessitating 671

perioperative intravitreal anti-VEGF agents and vigilant postoperative follow-up ^[27, 28]. Therefore, ophthalmologists should prioritize strengthening DR screening and
 follow-up for diabetic patients undergoing cataract surgery. This approach is crucial
 to identify DR promptly and prevent further deterioration of vision due to DR.

Ophthalmologists must prioritize regular follow-ups and effectively communicate 676 to patients undergoing PRP treatment about ongoing examinations' importance. Our 677 study observed that 16 patients with PDR had completed PRP treatment, but their 678 condition continued progressing. Among these patients, 11 were unaware of the 679 necessity for regular post-PRP examinations, and ten believed that their vision had 680 stabilized, leading them to forego further treatment. Unfortunately, this delay in 681 disease detection hindered early intervention. Furthermore, we discovered that six 682 patients needed complete PRP treatment and were frequently required to pay more 683 attention to follow-up examinations. Consequently, their condition progressed, 684 ultimately requiring vitrectomy surgery. Previous research has demonstrated that 685 effective PRP treatment can prevent 50% of PDR progression and mitigate 50% of 686 severe vision damage caused by PDR^[29]. However, despite PRP treatment, 42% of 687 PDR patients still experience disease progression [30]. Patients who initiate PRP 688 treatment after experiencing vitreous hemorrhage and retinal detachment are more 689 likely to encounter DR progression following PRP treatment [30, 31]. Therefore, for 690 diabetic patients who have completed PRP treatment, ophthalmologists should 691 strengthen education regarding the effectiveness of PRP treatment and stress the 692 need for regular follow-up examinations. It is crucial to adhere to standardized PRP 693

treatment protocols meticulously.

695 Limitations:

This study is a cross-sectional survey that focused on PDR patients who delayed 696 seeking medical treatment. The study specifically excluded patients with well-697 controlled glucose levels and those compliant with DR treatment, and we could not 698 investigate the delayed presentation in those patients. Notably, this study's proportion 699 of patients receiving intravitreal anti-VEGF agents was relatively low. Furthermore, 700 most patients who received this treatment did so after experiencing vitreous 701 hemorrhage or NVG. Therefore, the reasons for the delayed progression of PDR 702 following intravitreal anti-VEGF agents remain unclear, indicating a need for further 703 research. Additionally, it is worth mentioning that the number of patients who 704 underwent PRP received intravitreal anti-VEGF agents or cataract surgery was 705 relatively small. This may have resulted in a selection bias among the study 706 population. Furthermore, regarding retinopathy assessment, this study did not include 707 the measurement of VA. Instead, the patient's ocular condition was evaluated solely 708 through fundus examination. Consequently, the study failed to demonstrate any visual 709 acuity impairment within this group of patients. Regarding systemic examination, the 710 study exclusively recorded the patient's medical history of coronary artery disease 711 (CAD), cerebral infarction, and other diseases and the results of kidney function tests. 712 However, urine albumin-to-creatinine ratio (ACR) examinations were not conducted, 713 leading to a deviation in evaluating the systemic condition. 714

715 **Conclusions:**

This study investigated the factors contributing to delayed presentation among 716 patients with PDR. A significant proportion of individuals in the delayed population 717 were found to have undiagnosed DM. As a result, it is crucial to enhance DM 718 719 screening efforts and promote education about the condition. Among patients already aware of their DM status, reasons for delay included insufficient knowledge about DR, 720 negative attitudes towards screening and treatment, and difficulties seeking medical 721 care in real-life situations. Furthermore, there needed to be more improvements in the 722 detection, treatment, and follow-up of DR by both internal medicine practitioners and 723 ophthalmologists. It is imperative to strengthen education regarding the importance of 724 regular DR screening, especially when it still needs to impact vision. Particular 725 attention should be given to patients with irregular visits to internal medicine 726 specialists and those concerned about discomfort during DR treatment. Additionally, 727 patients who undergo cataract surgery, participate in DR screening conducted by 728 physicians, utilize traditional Chinese medicine treatments, complete PRP, and have 729 negative screening findings should also receive regular follow-up examinations. 730 Finally, vigilance to patients' challenges during the diagnosis and treatment process is 731 crucial. Patients should be encouraged to cooperate and receive support from family 732 members throughout their treatment journey. 733

734

735

736

737 **References:**

1. Cheung N, P Mitchell, TY Wong. Diabetic retinopathy. Lancet. 2010; 376: p. 124-

739 36.10.1016/s0140-6736(09)62124-3.

- 2. Lin KY, WH Hsih, YB Lin, CY Wen, TJ Chang. Update in the epidemiology, risk
- factors, screening, and treatment of diabetic retinopathy. J Diabetes Investig.
 2021; 12: p. 1322-1325.10.1111/jdi.13480.
- 743 3. Flaxel CJ, RA Adelman, ST Bailey, A Fawzi, JI Lim, GA Vemulakonda, et al.
- Diabetic Retinopathy Preferred Practice Pattern®. Ophthalmology. 2020; 127: p.
 P66-p145.10.1016/j.ophtha.2019.09.025.
- 4. Self-reported visual impairment among persons with diagnosed diabetes --United States, 1997--2010. MMWR Morb Mortal Wkly Rep. 2011; 60: p. 1549-
- 748 53
- Tracey ML, SM McHugh, AP Fitzgerald, CM Buckley, RJ Canavan, PM Kearney.
 Trends in blindness due to diabetic retinopathy among adults aged 18-69years
 over a decade in Ireland. Diabetes Res Clin Pract. 2016; 121: p. 18.10.1016/j.diabres.2016.08.016.
- Nwanyanwu K, M Nunez-Smith, TW Gardner, MM Desai. Awareness of Diabetic
 Retinopathy: Insight From the National Health and Nutrition Examination Survey.
 Am J Prev Med. 2021; 61: p. 900-909.10.1016/j.amepre.2021.05.018.
- 756 7. Xu T, B Wang, H Liu, H Wang, P Yin, W Dong, et al. Prevalence and causes of
 757 vision loss in China from 1990 to 2019: findings from the Global Burden of

- Disease Study 2019. Lancet Public Health. 2020; 5: p. e682-e691.10.1016/s24682667(20)30254-1.
- Kashim RM, P Newton,O Ojo. Diabetic Retinopathy Screening: A Systematic
 Review on Patients' Non-Attendance. Int J Environ Res Public Health. 2018;
 15.10.3390/ijerph15010157.
- 9. Sen A, P Pathak, P Shenoy, GM Kohli, P Bhatia,S Shetty. Knowledge, attitude,
 and practice patterns and the purported reasons for delayed presentation of
 patients with sight-threatening diabetic retinopathy at a tertiary eyecare facility in
 Central India: A questionnaire-based study. Indian J Ophthalmol. 2021; 69: p.
 3118-3122.10.4103/ijo.IJO 1503 21.
- 10. Ohlhausen M, C Payne, T Greenlee, AX Chen, T Conti, RP Singh. Impact and 768 Characterization of Delayed Pan-Retinal Photocoagulation in Proliferative 769 Diabetic Retinopathy. Ophthalmol. 223: 267-Am J 2021; 770 p. 274.10.1016/j.ajo.2020.09.051. 771
- Gulliford MC, H Dodhia, M Chamley, K McCormick, M Mohamed, S Naithani,
 et al. Socio-economic and ethnic inequalities in diabetes retinal screening. Diabet
 Med. 2010; 27: p. 282-8.10.1111/j.1464-5491.2010.02946.x.
- Negretti GS, R Amin, L Webster, CA Egan. Does delay in referral of proliferative
 diabetic retinopathy from the diabetic eye screening programme lead to visual
 loss? Eye (Lond). 2016; 30: p. 873-6.10.1038/eye.2016.56.
- Mozaffarieh M, T Benesch, S Sacu, K Krepler, R Biowski, A Wedrich.
 Photocoagulation for diabetic retinopathy: determinants of patient satisfaction
 - 40

- and the patient-provider relationship. Acta Ophthalmol Scand. 2005; 83: p. 31621.10.1111/j.1600-0420.2005.00455.x.
- Scanlon PH, ML Martin, C Bailey, E Johnson, P Hykin,S Keightley. Reported
 symptoms and quality-of-life impacts in patients having laser treatment for sightthreatening diabetic retinopathy. Diabet Med. 2006; 23: p. 60-6.10.1111/j.14645491.2005.01736.x.
- Gorst C, CS Kwok, S Aslam, I Buchan, E Kontopantelis, PK Myint, et al. Longterm Glycemic Variability and Risk of Adverse Outcomes: A Systematic Review
 and Meta-analysis. Diabetes Care. 2015; 38: p. 2354-69.10.2337/dc15-1188.
- 16. Sobrin L. Longitudinal validation of hemoglobin A(1c) criteria for diabetes
 diagnosis: risk of retinopathy. Diabetes. 2012; 61: p. 3074-5.10.2337/db12-1226.
- 17. Vasilijević JB, IM Kovačević, ZM Bukumirić, GD Marić, NA Slijepčević, TD
 Pekmezović. Vision-Related Quality of Life and Treatment Satisfaction
 Following Panretinal Photocoagulation in Diabetic Retinopathy-A Panel Study.
 Medicina (Kaunas). 2022; 58.10.3390/medicina58121741.
- 18. Azarcon CP,JCM Artiaga. Comparison of Pain Scores Among Patients
 Undergoing Conventional and Novel Panretinal Photocoagulation for Diabetic
 Retinopathy: A Systematic Review. Clin Ophthalmol. 2021; 15: p. 953971.10.2147/opth.S294227.
- Fenwick E, G Rees, K Pesudovs, M Dirani, R Kawasaki, TY Wong, et al. Social
 and emotional impact of diabetic retinopathy: a review. Clin Exp Ophthalmol.
 2012; 40: p. 27-38.10.1111/j.1442-9071.2011.02599.x.
 - 41

- Kaushik M, S Nawaz,TS Qureshi. Profile of sight-threatening diabetic
 retinopathy and its awareness among patients with diabetes mellitus attending a
 tertiary care center in Kashmir, India. Indian J Ophthalmol. 2021; 69: p. 31233130.10.4103/ijo.IJO_831_21.
- Xu L, S Chen, K Xu, Y Wang, H Zhang, L Wang, et al. Prevalence and associated
 factors of depression and anxiety among Chinese diabetic retinopathy patients: A
 cross-sectional study. PLoS One. 2022; 17: p.
 e0267848.10.1371/journal.pone.0267848.
- Begum T, A Rahman, D Nomani, A Mamun, A Adams, S Islam, et al. Diagnostic
 Accuracy of Detecting Diabetic Retinopathy by Using Digital Fundus
 Photographs in the Peripheral Health Facilities of Bangladesh: Validation Study.
 JMIR Public Health Surveill. 2021; 7: p. e23538.10.2196/23538.
- Jani PD, L Forbes, A Choudhury, JS Preisser, AJ Viera, S Garg. Evaluation of 23. 814 Diabetic Retinal Screening and Factors for Ophthalmology Referral in a 815 Telemedicine Network. JAMA Ophthalmol. 706-816 2017; 135: p. 714.10.1001/jamaophthalmol.2017.1150. 817
- Scanlon PH. The contribution of the English NHS Diabetic Eye Screening 24. 818 Programme to reductions in diabetes-related blindness, comparisons within 819 and future challenges. Diabetol. 2021; 820 Europe, Acta 58: p. 521-530.10.1007/s00592-021-01687-w. 821
- Pang B, QW Li, YL Qin, GT Dong, S Feng, J Wang, et al. Traditional chinese
 medicine for diabetic retinopathy: A systematic review and meta-analysis.
 - 42

Medicine (Baltimore). 2020; 99: p. e19102.10.1097/md.000000000019102.

- Zhang HW, H Zhang, SJ Grant, X Wan,G Li. Single herbal medicine for diabetic
 retinopathy. Cochrane Database Syst Rev. 2018; 12: p.
 Cd007939.10.1002/14651858.CD007939.pub2.
- Peterson SR, PA Silva, TJ Murtha, JK Sun. Cataract Surgery in Patients with
 Diabetes: Management Strategies. Semin Ophthalmol. 2018; 33: p. 7582.10.1080/08820538.2017.1353817.
- 28. Chu CJ, RL Johnston, C Buscombe, AB Sallam, Q Mohamed, YC Yang. Risk 831 Factors and Incidence of Macular Edema after Cataract Surgery: A Database 832 Study of 81984 Eyes. Ophthalmology. 2016; 123: 316-833 p. 323.10.1016/j.ophtha.2015.10.001. 834
- Evans JR, M Michelessi, G Virgili. Laser photocoagulation for proliferative
 diabetic retinopathy. Cochrane Database Syst Rev. 2014; 2014: p.
 Cd011234.10.1002/14651858.CD011234.pub2.
- Bressler SB, WT Beaulieu, AR Glassman, JG Gross, LM Jampol, M Melia, et al.
 Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes
 Treated with Panretinal Photocoagulation or Ranibizumab. Ophthalmology. 2017;
 124: p. 431-439.10.1016/j.ophtha.2016.12.005.
- Fallico M, A Maugeri, A Lotery, A Longo, V Bonfiglio, A Russo, et al.
 Intravitreal anti-vascular endothelial growth factors, panretinal photocoagulation
 and combined treatment for proliferative diabetic retinopathy: a systematic
 review and network meta-analysis. Acta Ophthalmol. 2021; 99: p. e795-

e805.10.1111/aos.14681.

847

848

Abbreviations:		
AIC	Akaike information criterion	
CKD	chronic kidney disease	
DR	diabetic retinopathy	
HbA1c	glycated hemoglobin level	
HTN	hypertension	
IV	intravitreal injection	
NVI	neovascularization of the iris	
NVG	neovascular glaucoma	
PDR	proliferative diabetic retinopathy	
PRP	pan-retinal photocoagulation	
VEGF	vascular endothelial growth factor	
VH	vitreous hemorrhage	

849 Acknowledgements

850 We would like to express our sincere gratitude to all those who contributed to the

successful completion of this study. Their support, guidance, and encouragement have

been invaluable throughout the research process.

First and foremost, we extend our heartfelt appreciation to the patients who

participated in this study. Their willingness to share their experiences and insights

- played a pivotal role in shedding light on the factors contributing to delayed
- presentation in patients with proliferative diabetic retinopathy.
- 857 We are grateful to our colleagues and fellow researchers who provided valuable
- ⁸⁵⁸ feedback and suggestions during the course of this study. Their expertise greatly
- enriched the quality of our research.

